Levemir® insulin, in both its Penfill® and Flexpen® presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been issued regarding the discontinuation.
In response to this, the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society have published joint guidance from a multidisciplinary team of healthcare professionals, which aims to support clinicians in appropriately selecting and safely prescribing alternative insulin therapy.
